Article Data

  • Views 371
  • Dowloads 150

Case Reports

Open Access

Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report

  • J.J. Noh1
  • H. Jung2
  • C.H. Choi1,*,

1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

2Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

DOI: 10.12892/ejgo4827.2019 Vol.40,Issue 4,August 2019 pp.679-683

Accepted: 19 July 2018

Published: 10 August 2019

*Corresponding Author(s): C.H. Choi E-mail:


The authors describe a case of a mesonephric adenocarcinoma of the meso-ovarium and meso-salpinx in a 52-year-old woman. The patient underwent total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, followed by adjuvant chemotherapy with paclitaxel and carboplatin for six cycles with three-week intervals in between. The patient remained free of disease for 18 months with good general conditions. They also reviewed the clinical, pathological, and immunohistochemical characteristics of 42 published case reports of mesonephric adenocarcinoma. The most common presentation of the disease was vaginal bleeding, followed by low abdominal pain. Among the 42 cases reviewed, only three patients were given the correct diagnosis preoperatively. A significant portion of them showed positive immunoreactivity for CD10, vimentin, and calretinin. The authors also found that AE1/AE3, CK7, EMA, CD10, and vimentin are typically positive while ER, PR, and CEA are usually negative. Among the cases reviewed, adjuvant chemotherapy was performed in 11 (26.2%) patients while adjuvant radiotherapy was performed in 16 (38.1%) patients. A number of chemotherapeutic regimens have been used but responses to such regimens are still inconclusive. Although further experiences are needed, surgical removal of the mass followed by paclitaxel and carboplatin adjuvant chemotherapy may be considered as a viable option for treatment.


Mesonephric adenocarcinoma; Hysterectomy; Chemotherapy; Paclitaxel; Carboplatin

Cite and Share

J.J. Noh,H. Jung,C.H. Choi. Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report. European Journal of Gynaecological Oncology. 2019. 40(4);679-683.


[1] Bague S., Rodriguez I.M., Prat J.: “Malignant mesonephric tumors of the female genital tract: a clinicopathologic study of 9 cases”. Am. J. Surg. Pathol., 2004, 28, 601.

[2] McCluggage W.G., Oliva E., Herrington C.S., McBride H., Young R.H.: “CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma”. Histopathology, 2003, 43, 144.

[3] Clement P.B., Young R.H., Keh P., Ostor A.G., Scully R.E.: “Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component”. Am. J. Surg. Pathol., 1995, 19, 1158.

[4] Lang G., Dallenbach-Hellweg G.: “The histogenetic origin of cervical mesonephric hyperplasia and mesonephric adenocarcinoma of the uterine cervix studied with immunohistochemical methods”. Int. J. Gynecol. Pathol., 1990, 9, 145.

[5] Silver S.A., Devouassoux-Shisheboran M., Mezzetti T.P., Tavassoli F.A.: “Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings”. Am. J. Surg. Pathol., 2001, 25, 379.

[6] Valente P.T., Susin M.: “Cervical adenocarcinoma arising in florid mesonephric hyperplasia: report of a case with immunocytochemical studies”. Gynecol. Oncol., 1987, 27, 58.

[7] Montagut C., Marmol M., Rey V., Ordi J., Pahissa J., Rovirosa A., et al.: “Activity of chemotherapy with carboplatin plus paclitaxel in a recurrent mesonephric adenocarcinoma of the uterine corpus”. Gynecol. Oncol., 2003, 90, 458.

[8] Buntine D.W.: “Adenocarcinoma of the uterine cervix of probable Wolffian origin”. Pathology, 1979, 11, 713.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time